MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet and exercise alone, others find that adding weight loss medications like ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

Patients with obesity, with or without diabetes, lose up to 20% body weight and show A1c reductions with the novel agent maridebart cafraglutide, though nearly all experience GI side effects.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...

They also have strong dividend track records. Apple and Amgen have lagged the market over the trailing-12-month period, but ...